Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized open label study, with 2 arms treatments conducted in patients with
metastatic or unresectable advanced sarcoma of rare subtype; previously treated by
anthracycline-based regimen except for whom standard therapy does not exist or is not
considered appropriate by the Investigator.
In the experimental arm, patients will receive the combination of Nivolumab + Ipilimumab for
a maximum of 12 months, whereas in the control arm, patients will receive Pazopanib alone for
12 months.
The purpose of the study is to know if the combination of nivolumab + ipilimumab can be more
efficient than Pazopanib in terms of Progression-Free Survival.